company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6525000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6525000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6525000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3257000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7147000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10404000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3879000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3879000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,19000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3860000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3860000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3860000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.09
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.09
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45157000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:04:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.09
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2943000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2943000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2943000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2889000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8769000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11658000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8715000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8715000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,20000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8695000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8695000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8695000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45201000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 15:46:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2200000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2200000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2200000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3539000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8262000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11801000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9601000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9601000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,23000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9578000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9578000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9578000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,45600000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,45600000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45461000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q1,2011-01-01,2011-03-31,2012-05-07 17:16:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1514000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1514000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1514000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3676000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8119000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11795000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10281000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10281000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,22000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10259000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10259000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10259000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51300000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51300000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 15:31:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1857000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1857000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1857000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3592000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7839000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11431000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9574000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9574000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,20000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9554000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9554000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9554000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53100000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53100000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52464000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q3,2011-07-01,2011-09-30,2012-11-02 15:33:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4748000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4748000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4748000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3235000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7878000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11113000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6365000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6365000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,6000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6359000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6359000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6359000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50400000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50400000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50512000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3242000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3242000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3242000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3242000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7283000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10525000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7283000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,15000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,15000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7268000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7268000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7268000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7268000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52567000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 13:41:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4574000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4574000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4574000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2744000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7574000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10318000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5744000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,16000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,16000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5728000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5728000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5728000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5728000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52100000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52100000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52657000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:50:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4907000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4907000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4907000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3139000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7570000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10709000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5802000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,12000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5790000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5790000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5790000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5790000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52600000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52600000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52768000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 16:50:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8932000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8932000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8932000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3019000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9282000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12301000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3369000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-43000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-43000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3412000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-66000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3478000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3478000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3478000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53000000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.06
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53000000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.06
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52741000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.06
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4623000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4623000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4623000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3308000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8220000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11528000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6905000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,20000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,20000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6885000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6885000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6885000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6885000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53000000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53000000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,53377000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:56:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6934000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6934000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6934000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3124000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9278000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12402000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5468000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,18000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,18000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5450000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5450000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5450000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5450000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,54500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,53786000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:25:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5707000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5707000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5707000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3163000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8703000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11866000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6159000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,14000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,14000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6145000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6145000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6145000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6145000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,55900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,55900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,54786000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 16:32:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8116000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8116000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8116000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3644000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12083000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15727000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7611000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,39000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,39000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7572000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7572000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7572000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7572000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,63100000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,63100000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,63199000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q1,2014-01-01,2014-03-31,2015-04-28 16:32:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10385000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10385000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10385000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3972000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13460000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17432000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7047000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,66000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,66000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6981000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6981000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6981000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6981000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,67980000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 16:37:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12417000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12417000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12417000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3731000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16340000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20071000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7654000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,109000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,109000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7545000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7545000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7545000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7545000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68600000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68600000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,68230000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:51:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14952000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14952000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14952000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4330000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15091000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19421000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4469000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-214000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,364000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,150000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4319000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4319000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4319000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4319000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,67700000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.06
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,67700000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.06
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,67022000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.06
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13491000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13491000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13491000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4732000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14980000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19712000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6221000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,154000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,154000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6067000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-748000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5319000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5319000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5319000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,66500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.08
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,66500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.08
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69283000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:29:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.08
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8358000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8358000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8358000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5017000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15618000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20635000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12277000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,151000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,151000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12126000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12126000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12126000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12126000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71300000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,71300000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69684000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:23:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8569000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8569000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8569000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4560000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16694000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21254000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12685000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,101000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,101000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12584000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3339000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9245000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9245000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9245000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71100000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,71100000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69892000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:36:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9121000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9121000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9121000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4888000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19906000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24794000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15673000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,25000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,25000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15648000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1635000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14013000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14013000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14013000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70200000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70200000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69757000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3942000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3942000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3942000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5357000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15266000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20623000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16681000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,187000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,187000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16494000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16494000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16494000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16494000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71700000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,71700000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70373000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 16:56:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3702000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3702000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3702000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11090000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19454000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30544000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26842000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,243000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,243000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26599000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-24000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26575000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26575000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26575000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.38
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.38
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70487000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:46:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.38
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2823000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2823000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2823000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5021000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17008000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22029000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19206000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,238000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,238000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18968000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18965000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18965000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18965000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70200000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.27
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70200000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70618000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:24:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8922000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8922000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8922000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4862000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13890000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18752000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9830000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,219000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,219000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9611000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,13000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9624000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9624000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9624000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70300000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70300000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70553000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3425000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3425000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3425000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7275000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12942000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20217000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16792000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,160000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,160000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16632000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16632000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16632000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16632000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,72300000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,72300000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71025000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 21:57:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8253000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8253000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8253000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6037000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14984000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21021000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12768000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,277000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,277000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12491000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12491000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12491000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12491000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,73500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,73500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,72527000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:37:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11812000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11812000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,11812000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6422000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18425000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24847000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13035000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,681000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,681000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12354000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12354000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12354000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12354000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,82400000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,82400000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,83750000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:09:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13077000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13077000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13077000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7466000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19377000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26843000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13766000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,675000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,675000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13091000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13091000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13091000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13091000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,78000000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,78000000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,78084000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12637000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12637000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12637000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10087000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23547000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33634000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20997000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,810000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,810000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20187000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20187000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20187000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20187000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,87800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,87800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,86334000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 16:34:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21416000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21416000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21416000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11301000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,29255000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,40556000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19140000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16640000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16640000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16640000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16640000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,97900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,97900000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,97267000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:44:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23562000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23562000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23562000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10993000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,28810000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39803000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16241000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3398000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3398000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12843000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12843000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12843000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12843000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,98800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,98800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,101725000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:33:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,26837000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,26837000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,26837000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14355000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33254000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,47609000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20772000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1553000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1553000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19219000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19219000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19219000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-555000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18664000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,97600000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,97600000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,96941000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8071000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8071000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8071000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17118000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,34850000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51968000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-43897000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1694000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1694000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-42203000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-42203000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-42203000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-53000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-42150000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,102800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,102800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,102270000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:27:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,17548000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,17548000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17548000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14597000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,36455000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51052000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33504000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3148000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3148000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30356000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30356000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30356000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-72000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30284000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,116500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,116500000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,114382000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:44:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21958000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21958000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21958000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14918000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,36288000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51206000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29248000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1887000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1887000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27361000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27361000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27361000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-54000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27307000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,113800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,113800000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,115710000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:33:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,54851000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,54851000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,54851000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,15053000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,38329000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,53382000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1469000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3032000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3032000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4501000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4501000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4501000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-54000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4555000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,112000000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.06
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,112000000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.06
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112114000.0
Sangamo Therapeutics Inc,SGMO,,0001001233,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.06
